Last updated: 2026-02-23 07:59:51 ET
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine po...
The Trump administration appears to be gearing up for a substantial response to Iran, Washington state allegedly spends millions on gender surgeries f...
The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the company's application to market...
Makary pointed to three bottlenecks: hospital contracting, ethical reviews and approvals and the Investigational New Drug applications process
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.
Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to rejec...
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal inf...
In February 2026, Moderna reported full-year 2025 revenue of US$1.94 billion and a net loss of US$2.82 billion, while the FDA’s vaccines ...
